nodes	percent_of_prediction	percent_of_DWPC	metapath
Salicylate-sodium—PTGS1—esophageal cancer	0.492	0.636	CbGaD
Salicylate-sodium—PTGS2—esophageal cancer	0.281	0.364	CbGaD
Salicylate-sodium—PTGS2—Cisplatin—esophageal cancer	0.0775	1	CbGbCtD
Salicylate-sodium—Venous thrombosis—Carboplatin—esophageal cancer	0.00531	0.0543	CcSEcCtD
Salicylate-sodium—Fluid overload—Carboplatin—esophageal cancer	0.00461	0.0471	CcSEcCtD
Salicylate-sodium—Extravasation—Carboplatin—esophageal cancer	0.00329	0.0336	CcSEcCtD
Salicylate-sodium—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—ALOX15—esophageal cancer	0.00312	0.0724	CbGpPWpGaD
Salicylate-sodium—Bronchopneumonia—Capecitabine—esophageal cancer	0.00284	0.029	CcSEcCtD
Salicylate-sodium—Acetylsalicylic acid—HSPA5—esophageal cancer	0.00264	0.352	CrCbGaD
Salicylate-sodium—Tetany—Cisplatin—esophageal cancer	0.00258	0.0264	CcSEcCtD
Salicylate-sodium—Phlebitis—Carboplatin—esophageal cancer	0.00242	0.0247	CcSEcCtD
Salicylate-sodium—Localized exfoliation—Capecitabine—esophageal cancer	0.0023	0.0235	CcSEcCtD
Salicylate-sodium—Venous thrombosis—Cisplatin—esophageal cancer	0.00156	0.0159	CcSEcCtD
Salicylate-sodium—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—esophageal cancer	0.0014	0.0324	CbGpPWpGaD
Salicylate-sodium—Fluid overload—Cisplatin—esophageal cancer	0.00135	0.0138	CcSEcCtD
Salicylate-sodium—Swelling face—Capecitabine—esophageal cancer	0.0013	0.0133	CcSEcCtD
Salicylate-sodium—PTGS1—Eicosanoid Synthesis—ALOX15—esophageal cancer	0.0013	0.0301	CbGpPWpGaD
Salicylate-sodium—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—esophageal cancer	0.00121	0.0281	CbGpPWpGaD
Salicylate-sodium—Intestinal perforation—Methotrexate—esophageal cancer	0.00117	0.0119	CcSEcCtD
Salicylate-sodium—Venous thrombosis—Capecitabine—esophageal cancer	0.00115	0.0117	CcSEcCtD
Salicylate-sodium—PTGS2—Calcium signaling in the CD4+ TCR pathway—FKBP1A—esophageal cancer	0.00114	0.0264	CbGpPWpGaD
Salicylate-sodium—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS1—esophageal cancer	0.0011	0.0255	CbGpPWpGaD
Salicylate-sodium—Acetylsalicylic acid—TP53—esophageal cancer	0.00108	0.145	CrCbGaD
Salicylate-sodium—Necrosis—Cisplatin—esophageal cancer	0.00107	0.011	CcSEcCtD
Salicylate-sodium—Gastric ulcer—Capecitabine—esophageal cancer	0.00107	0.0109	CcSEcCtD
Salicylate-sodium—Abscess—Cisplatin—esophageal cancer	0.00106	0.0109	CcSEcCtD
Salicylate-sodium—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—CYP2A6—esophageal cancer	0.00104	0.0241	CbGpPWpGaD
Salicylate-sodium—PTGS2—Eicosanoid Synthesis—ALOX15—esophageal cancer	0.00103	0.0239	CbGpPWpGaD
Salicylate-sodium—Infection—Carboplatin—esophageal cancer	0.00102	0.0104	CcSEcCtD
Salicylate-sodium—Extravasation—Cisplatin—esophageal cancer	0.000964	0.00985	CcSEcCtD
Salicylate-sodium—Tenderness—Cisplatin—esophageal cancer	0.000964	0.00985	CcSEcCtD
Salicylate-sodium—Cellulitis—Cisplatin—esophageal cancer	0.000925	0.00945	CcSEcCtD
Salicylate-sodium—Intestinal obstruction—Capecitabine—esophageal cancer	0.000909	0.0093	CcSEcCtD
Salicylate-sodium—Ulcer—Cisplatin—esophageal cancer	0.000889	0.00909	CcSEcCtD
Salicylate-sodium—Hearing impaired—Cisplatin—esophageal cancer	0.000883	0.00903	CcSEcCtD
Salicylate-sodium—Pain—Carboplatin—esophageal cancer	0.000875	0.00894	CcSEcCtD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—PTGS1—esophageal cancer	0.00086	0.0199	CbGpPWpGaD
Salicylate-sodium—Body temperature increased—Carboplatin—esophageal cancer	0.000809	0.00827	CcSEcCtD
Salicylate-sodium—Skin exfoliation—Cisplatin—esophageal cancer	0.000803	0.00821	CcSEcCtD
Salicylate-sodium—Fluid retention—Cisplatin—esophageal cancer	0.000798	0.00816	CcSEcCtD
Salicylate-sodium—Coagulopathy—Capecitabine—esophageal cancer	0.000796	0.00814	CcSEcCtD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—HMOX1—esophageal cancer	0.00079	0.0183	CbGpPWpGaD
Salicylate-sodium—Tingling sensation—Capecitabine—esophageal cancer	0.000771	0.00788	CcSEcCtD
Salicylate-sodium—PTGS1—Prostaglandin Synthesis and Regulation—ANXA1—esophageal cancer	0.000737	0.0171	CbGpPWpGaD
Salicylate-sodium—PTGS1—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00072	0.0167	CbGpPWpGaD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—BAX—esophageal cancer	0.000717	0.0166	CbGpPWpGaD
Salicylate-sodium—PTGS2—Eicosanoid Synthesis—PTGS1—esophageal cancer	0.000713	0.0165	CbGpPWpGaD
Salicylate-sodium—Phlebitis—Cisplatin—esophageal cancer	0.000709	0.00724	CcSEcCtD
Salicylate-sodium—Deafness—Cisplatin—esophageal cancer	0.000682	0.00698	CcSEcCtD
Salicylate-sodium—Cellulitis—Capecitabine—esophageal cancer	0.000682	0.00697	CcSEcCtD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—PRDX2—esophageal cancer	0.000678	0.0157	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—PRDX1—esophageal cancer	0.000678	0.0157	CbGpPWpGaD
Salicylate-sodium—Hypocalcaemia—Capecitabine—esophageal cancer	0.000677	0.00692	CcSEcCtD
Salicylate-sodium—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000673	0.00688	CcSEcCtD
Salicylate-sodium—Burning sensation—Methotrexate—esophageal cancer	0.000664	0.00679	CcSEcCtD
Salicylate-sodium—Renal failure acute—Cisplatin—esophageal cancer	0.000661	0.00676	CcSEcCtD
Salicylate-sodium—Ulcer—Capecitabine—esophageal cancer	0.000655	0.0067	CcSEcCtD
Salicylate-sodium—Cyanosis—Methotrexate—esophageal cancer	0.000652	0.00666	CcSEcCtD
Salicylate-sodium—Hearing impaired—Capecitabine—esophageal cancer	0.000651	0.00666	CcSEcCtD
Salicylate-sodium—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC52A3—esophageal cancer	0.000639	0.0148	CbGpPWpGaD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000635	0.0147	CbGpPWpGaD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—HMOX1—esophageal cancer	0.000627	0.0146	CbGpPWpGaD
Salicylate-sodium—Cerebrovascular accident—Cisplatin—esophageal cancer	0.000623	0.00637	CcSEcCtD
Salicylate-sodium—PTGS2—Prostaglandin Synthesis and Regulation—PTGS1—esophageal cancer	0.000596	0.0138	CbGpPWpGaD
Salicylate-sodium—Skin exfoliation—Capecitabine—esophageal cancer	0.000592	0.00605	CcSEcCtD
Salicylate-sodium—Fluid retention—Capecitabine—esophageal cancer	0.000588	0.00602	CcSEcCtD
Salicylate-sodium—Necrosis—Methotrexate—esophageal cancer	0.000588	0.00601	CcSEcCtD
Salicylate-sodium—PTGS2—Prostaglandin Synthesis and Regulation—ANXA1—esophageal cancer	0.000585	0.0136	CbGpPWpGaD
Salicylate-sodium—Magnesium salicylate—PTGS1—esophageal cancer	0.000584	0.078	CrCbGaD
Salicylate-sodium—Abscess—Methotrexate—esophageal cancer	0.000583	0.00596	CcSEcCtD
Salicylate-sodium—Irritability—Cisplatin—esophageal cancer	0.000583	0.00596	CcSEcCtD
Salicylate-sodium—PTGS2—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.000572	0.0133	CbGpPWpGaD
Salicylate-sodium—Blood creatinine increased—Cisplatin—esophageal cancer	0.000572	0.00585	CcSEcCtD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—BAX—esophageal cancer	0.000569	0.0132	CbGpPWpGaD
Salicylate-sodium—Dehydration—Cisplatin—esophageal cancer	0.000568	0.0058	CcSEcCtD
Salicylate-sodium—Oesophagitis—Capecitabine—esophageal cancer	0.000566	0.00579	CcSEcCtD
Salicylate-sodium—Ecchymosis—Capecitabine—esophageal cancer	0.00056	0.00573	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CA1—esophageal cancer	0.000559	0.013	CbGpPWpGaD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000557	0.0129	CbGpPWpGaD
Salicylate-sodium—Hypokalaemia—Cisplatin—esophageal cancer	0.000555	0.00568	CcSEcCtD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—PRDX1—esophageal cancer	0.000539	0.0125	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—PRDX2—esophageal cancer	0.000539	0.0125	CbGpPWpGaD
Salicylate-sodium—Sepsis—Capecitabine—esophageal cancer	0.000538	0.0055	CcSEcCtD
Salicylate-sodium—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—esophageal cancer	0.00053	0.0123	CbGpPWpGaD
Salicylate-sodium—Extravasation—Methotrexate—esophageal cancer	0.000529	0.00541	CcSEcCtD
Salicylate-sodium—Phlebitis—Capecitabine—esophageal cancer	0.000522	0.00534	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—NFE2L2—esophageal cancer	0.00052	0.0121	CbGpPWpGaD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000518	0.012	CbGpPWpGaD
Salicylate-sodium—Sweating increased—Cisplatin—esophageal cancer	0.000514	0.00525	CcSEcCtD
Salicylate-sodium—Swelling—Capecitabine—esophageal cancer	0.00051	0.00521	CcSEcCtD
Salicylate-sodium—Abdominal discomfort—Cisplatin—esophageal cancer	0.000506	0.00517	CcSEcCtD
Salicylate-sodium—Deafness—Capecitabine—esophageal cancer	0.000503	0.00514	CcSEcCtD
Salicylate-sodium—Oliguria—Methotrexate—esophageal cancer	0.000501	0.00512	CcSEcCtD
Salicylate-sodium—Salsalate—PTGS1—esophageal cancer	0.000497	0.0663	CrCbGaD
Salicylate-sodium—Ulcer—Methotrexate—esophageal cancer	0.000488	0.00499	CcSEcCtD
Salicylate-sodium—Renal failure acute—Capecitabine—esophageal cancer	0.000487	0.00498	CcSEcCtD
Salicylate-sodium—Renal impairment—Capecitabine—esophageal cancer	0.000473	0.00483	CcSEcCtD
Salicylate-sodium—PTGS2—S1P1 pathway—KDR—esophageal cancer	0.000471	0.0109	CbGpPWpGaD
Salicylate-sodium—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000464	0.00474	CcSEcCtD
Salicylate-sodium—Renal failure—Cisplatin—esophageal cancer	0.000462	0.00473	CcSEcCtD
Salicylate-sodium—Myocardial infarction—Cisplatin—esophageal cancer	0.000461	0.00471	CcSEcCtD
Salicylate-sodium—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000459	0.00469	CcSEcCtD
Salicylate-sodium—Lethargy—Capecitabine—esophageal cancer	0.000459	0.00469	CcSEcCtD
Salicylate-sodium—Skin exfoliation—Methotrexate—esophageal cancer	0.000441	0.0045	CcSEcCtD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—BCL2—esophageal cancer	0.000437	0.0101	CbGpPWpGaD
Salicylate-sodium—Mesalazine—PTGS1—esophageal cancer	0.000431	0.0576	CrCbGaD
Salicylate-sodium—Irritability—Capecitabine—esophageal cancer	0.000429	0.00439	CcSEcCtD
Salicylate-sodium—PTGS1—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000425	0.00985	CbGpPWpGaD
Salicylate-sodium—Blood creatinine increased—Capecitabine—esophageal cancer	0.000422	0.00431	CcSEcCtD
Salicylate-sodium—Dehydration—Capecitabine—esophageal cancer	0.000418	0.00428	CcSEcCtD
Salicylate-sodium—Ecchymosis—Methotrexate—esophageal cancer	0.000417	0.00426	CcSEcCtD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—PTGS2—esophageal cancer	0.000415	0.00963	CbGpPWpGaD
Salicylate-sodium—Abdominal pain upper—Capecitabine—esophageal cancer	0.000411	0.0042	CcSEcCtD
Salicylate-sodium—Hypokalaemia—Capecitabine—esophageal cancer	0.000409	0.00419	CcSEcCtD
Salicylate-sodium—Sepsis—Methotrexate—esophageal cancer	0.0004	0.00409	CcSEcCtD
Salicylate-sodium—PTGS2—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000396	0.0092	CbGpPWpGaD
Salicylate-sodium—Tinnitus—Cisplatin—esophageal cancer	0.000394	0.00402	CcSEcCtD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000392	0.00911	CbGpPWpGaD
Salicylate-sodium—Abdominal distension—Capecitabine—esophageal cancer	0.000391	0.004	CcSEcCtD
Salicylate-sodium—Dysphagia—Capecitabine—esophageal cancer	0.000389	0.00398	CcSEcCtD
Salicylate-sodium—Asthma—Capecitabine—esophageal cancer	0.000389	0.00398	CcSEcCtD
Salicylate-sodium—Bronchospasm—Capecitabine—esophageal cancer	0.000383	0.00391	CcSEcCtD
Salicylate-sodium—Sweating increased—Capecitabine—esophageal cancer	0.000379	0.00387	CcSEcCtD
Salicylate-sodium—Arrhythmia—Cisplatin—esophageal cancer	0.000377	0.00386	CcSEcCtD
Salicylate-sodium—Bronchitis—Capecitabine—esophageal cancer	0.000374	0.00382	CcSEcCtD
Salicylate-sodium—Abdominal discomfort—Capecitabine—esophageal cancer	0.000373	0.00381	CcSEcCtD
Salicylate-sodium—Acetylsalicylic acid—PTGS1—esophageal cancer	0.000371	0.0496	CrCbGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—FKBP1A—esophageal cancer	0.000371	0.0086	CbGpPWpGaD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000369	0.00856	CbGpPWpGaD
Salicylate-sodium—Erythema—Cisplatin—esophageal cancer	0.000368	0.00376	CcSEcCtD
Salicylate-sodium—Renal failure acute—Methotrexate—esophageal cancer	0.000363	0.00371	CcSEcCtD
Salicylate-sodium—Flatulence—Cisplatin—esophageal cancer	0.000362	0.0037	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—esophageal cancer	0.00036	0.00836	CbGpPWpGaD
Salicylate-sodium—Weight increased—Capecitabine—esophageal cancer	0.000354	0.00362	CcSEcCtD
Salicylate-sodium—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO1—esophageal cancer	0.00035	0.00813	CbGpPWpGaD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—BCL2—esophageal cancer	0.000347	0.00805	CbGpPWpGaD
Salicylate-sodium—Vision blurred—Cisplatin—esophageal cancer	0.000346	0.00354	CcSEcCtD
Salicylate-sodium—PTGS1—Eicosanoid Synthesis—PTGS2—esophageal cancer	0.000344	0.00799	CbGpPWpGaD
Salicylate-sodium—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000342	0.00349	CcSEcCtD
Salicylate-sodium—Lethargy—Methotrexate—esophageal cancer	0.000342	0.00349	CcSEcCtD
Salicylate-sodium—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000342	0.00349	CcSEcCtD
Salicylate-sodium—Renal failure—Capecitabine—esophageal cancer	0.000341	0.00348	CcSEcCtD
Salicylate-sodium—Myocardial infarction—Capecitabine—esophageal cancer	0.00034	0.00347	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—ADH7—esophageal cancer	0.000337	0.00783	CbGpPWpGaD
Salicylate-sodium—PTGS2—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000337	0.00782	CbGpPWpGaD
Salicylate-sodium—Magnesium salicylate—PTGS2—esophageal cancer	0.000334	0.0446	CrCbGaD
Salicylate-sodium—Epistaxis—Capecitabine—esophageal cancer	0.000327	0.00334	CcSEcCtD
Salicylate-sodium—Irritability—Methotrexate—esophageal cancer	0.00032	0.00327	CcSEcCtD
Salicylate-sodium—Convulsion—Cisplatin—esophageal cancer	0.000318	0.00326	CcSEcCtD
Salicylate-sodium—Anxiety—Cisplatin—esophageal cancer	0.000312	0.00319	CcSEcCtD
Salicylate-sodium—Hepatitis—Capecitabine—esophageal cancer	0.000311	0.00318	CcSEcCtD
Salicylate-sodium—Hypoaesthesia—Capecitabine—esophageal cancer	0.00031	0.00317	CcSEcCtD
Salicylate-sodium—Salicylic acid—PTGS1—esophageal cancer	0.000306	0.0408	CrCbGaD
Salicylate-sodium—Oedema—Cisplatin—esophageal cancer	0.0003	0.00307	CcSEcCtD
Salicylate-sodium—Anaphylactic shock—Cisplatin—esophageal cancer	0.0003	0.00307	CcSEcCtD
Salicylate-sodium—Infection—Cisplatin—esophageal cancer	0.000298	0.00305	CcSEcCtD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000297	0.0069	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—ADH1B—esophageal cancer	0.000296	0.00687	CbGpPWpGaD
Salicylate-sodium—Erythema multiforme—Capecitabine—esophageal cancer	0.000294	0.00301	CcSEcCtD
Salicylate-sodium—Tachycardia—Cisplatin—esophageal cancer	0.000293	0.00299	CcSEcCtD
Salicylate-sodium—Tinnitus—Capecitabine—esophageal cancer	0.00029	0.00297	CcSEcCtD
Salicylate-sodium—Hyperhidrosis—Cisplatin—esophageal cancer	0.00029	0.00296	CcSEcCtD
Salicylate-sodium—Asthma—Methotrexate—esophageal cancer	0.000289	0.00296	CcSEcCtD
Salicylate-sodium—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—esophageal cancer	0.000288	0.00668	CbGpPWpGaD
Salicylate-sodium—Anorexia—Cisplatin—esophageal cancer	0.000286	0.00292	CcSEcCtD
Salicylate-sodium—Salsalate—PTGS2—esophageal cancer	0.000284	0.0379	CrCbGaD
Salicylate-sodium—Hypotension—Cisplatin—esophageal cancer	0.00028	0.00287	CcSEcCtD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00028	0.00649	CbGpPWpGaD
Salicylate-sodium—Arrhythmia—Capecitabine—esophageal cancer	0.000278	0.00284	CcSEcCtD
Salicylate-sodium—Abdominal discomfort—Methotrexate—esophageal cancer	0.000278	0.00284	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—CYP26A1—esophageal cancer	0.000275	0.00638	CbGpPWpGaD
Salicylate-sodium—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—esophageal cancer	0.000275	0.00638	CbGpPWpGaD
Salicylate-sodium—Erythema—Capecitabine—esophageal cancer	0.000271	0.00277	CcSEcCtD
Salicylate-sodium—Paraesthesia—Cisplatin—esophageal cancer	0.000269	0.00275	CcSEcCtD
Salicylate-sodium—Dyspnoea—Cisplatin—esophageal cancer	0.000267	0.00273	CcSEcCtD
Salicylate-sodium—Flatulence—Capecitabine—esophageal cancer	0.000267	0.00273	CcSEcCtD
Salicylate-sodium—Dysgeusia—Capecitabine—esophageal cancer	0.000265	0.00271	CcSEcCtD
Salicylate-sodium—Decreased appetite—Cisplatin—esophageal cancer	0.000261	0.00267	CcSEcCtD
Salicylate-sodium—Drowsiness—Methotrexate—esophageal cancer	0.000258	0.00264	CcSEcCtD
Salicylate-sodium—Pain—Cisplatin—esophageal cancer	0.000257	0.00262	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—GSTO1—esophageal cancer	0.000256	0.00594	CbGpPWpGaD
Salicylate-sodium—Vision blurred—Capecitabine—esophageal cancer	0.000255	0.00261	CcSEcCtD
Salicylate-sodium—Renal failure—Methotrexate—esophageal cancer	0.000254	0.00259	CcSEcCtD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—PTGS1—esophageal cancer	0.000252	0.00585	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000252	0.00585	CbGpPWpGaD
Salicylate-sodium—Feeling abnormal—Cisplatin—esophageal cancer	0.000247	0.00253	CcSEcCtD
Salicylate-sodium—Mesalazine—PTGS2—esophageal cancer	0.000246	0.0329	CrCbGaD
Salicylate-sodium—Epistaxis—Methotrexate—esophageal cancer	0.000243	0.00249	CcSEcCtD
Salicylate-sodium—Syncope—Capecitabine—esophageal cancer	0.000243	0.00248	CcSEcCtD
Salicylate-sodium—PTGS2—Spinal Cord Injury—LGALS3—esophageal cancer	0.000243	0.00563	CbGpPWpGaD
Salicylate-sodium—Palpitations—Capecitabine—esophageal cancer	0.000239	0.00245	CcSEcCtD
Salicylate-sodium—Loss of consciousness—Capecitabine—esophageal cancer	0.000238	0.00243	CcSEcCtD
Salicylate-sodium—Body temperature increased—Cisplatin—esophageal cancer	0.000237	0.00242	CcSEcCtD
Salicylate-sodium—Hepatitis—Methotrexate—esophageal cancer	0.000232	0.00237	CcSEcCtD
Salicylate-sodium—Chest pain—Capecitabine—esophageal cancer	0.000231	0.00236	CcSEcCtD
Salicylate-sodium—Anxiety—Capecitabine—esophageal cancer	0.00023	0.00235	CcSEcCtD
Salicylate-sodium—Confusional state—Capecitabine—esophageal cancer	0.000223	0.00228	CcSEcCtD
Salicylate-sodium—Oedema—Capecitabine—esophageal cancer	0.000221	0.00226	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Cisplatin—esophageal cancer	0.000221	0.00226	CcSEcCtD
Salicylate-sodium—Infection—Capecitabine—esophageal cancer	0.00022	0.00225	CcSEcCtD
Salicylate-sodium—Erythema multiforme—Methotrexate—esophageal cancer	0.000219	0.00224	CcSEcCtD
Salicylate-sodium—Shock—Capecitabine—esophageal cancer	0.000218	0.00222	CcSEcCtD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—SOD2—esophageal cancer	0.000217	0.00503	CbGpPWpGaD
Salicylate-sodium—Tinnitus—Methotrexate—esophageal cancer	0.000216	0.00221	CcSEcCtD
Salicylate-sodium—Tachycardia—Capecitabine—esophageal cancer	0.000216	0.00221	CcSEcCtD
Salicylate-sodium—Asthenia—Cisplatin—esophageal cancer	0.000215	0.0022	CcSEcCtD
Salicylate-sodium—Hyperhidrosis—Capecitabine—esophageal cancer	0.000214	0.00219	CcSEcCtD
Salicylate-sodium—Acetylsalicylic acid—PTGS2—esophageal cancer	0.000212	0.0283	CrCbGaD
Salicylate-sodium—Anorexia—Capecitabine—esophageal cancer	0.000211	0.00215	CcSEcCtD
Salicylate-sodium—PTGS2—Spinal Cord Injury—CXCL2—esophageal cancer	0.00021	0.00488	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—ALDH2—esophageal cancer	0.000208	0.00484	CbGpPWpGaD
Salicylate-sodium—Hypotension—Capecitabine—esophageal cancer	0.000207	0.00211	CcSEcCtD
Salicylate-sodium—Diarrhoea—Cisplatin—esophageal cancer	0.000205	0.0021	CcSEcCtD
Salicylate-sodium—Erythema—Methotrexate—esophageal cancer	0.000202	0.00206	CcSEcCtD
Salicylate-sodium—Paraesthesia—Capecitabine—esophageal cancer	0.000199	0.00203	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—GSTT1—esophageal cancer	0.000198	0.0046	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000198	0.00458	CbGpPWpGaD
Salicylate-sodium—Dysgeusia—Methotrexate—esophageal cancer	0.000198	0.00202	CcSEcCtD
Salicylate-sodium—Dyspnoea—Capecitabine—esophageal cancer	0.000197	0.00202	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—CYP2A6—esophageal cancer	0.000196	0.00455	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000196	0.00454	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—ANXA1—esophageal cancer	0.000196	0.00454	CbGpPWpGaD
Salicylate-sodium—Dyspepsia—Capecitabine—esophageal cancer	0.000195	0.00199	CcSEcCtD
Salicylate-sodium—Decreased appetite—Capecitabine—esophageal cancer	0.000192	0.00197	CcSEcCtD
Salicylate-sodium—PTGS1—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000191	0.00444	CbGpPWpGaD
Salicylate-sodium—Vomiting—Cisplatin—esophageal cancer	0.000191	0.00195	CcSEcCtD
Salicylate-sodium—Fatigue—Capecitabine—esophageal cancer	0.000191	0.00195	CcSEcCtD
Salicylate-sodium—Vision blurred—Methotrexate—esophageal cancer	0.00019	0.00194	CcSEcCtD
Salicylate-sodium—Rash—Cisplatin—esophageal cancer	0.000189	0.00193	CcSEcCtD
Salicylate-sodium—Pain—Capecitabine—esophageal cancer	0.000189	0.00193	CcSEcCtD
Salicylate-sodium—Constipation—Capecitabine—esophageal cancer	0.000189	0.00193	CcSEcCtD
Salicylate-sodium—Dermatitis—Cisplatin—esophageal cancer	0.000189	0.00193	CcSEcCtD
Salicylate-sodium—Feeling abnormal—Capecitabine—esophageal cancer	0.000182	0.00186	CcSEcCtD
Salicylate-sodium—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000181	0.00185	CcSEcCtD
Salicylate-sodium—Acetylsalicylic acid—ABCB1—esophageal cancer	0.00018	0.0241	CrCbGaD
Salicylate-sodium—Nausea—Cisplatin—esophageal cancer	0.000178	0.00182	CcSEcCtD
Salicylate-sodium—Urticaria—Capecitabine—esophageal cancer	0.000176	0.0018	CcSEcCtD
Salicylate-sodium—Abdominal pain—Capecitabine—esophageal cancer	0.000175	0.00179	CcSEcCtD
Salicylate-sodium—Body temperature increased—Capecitabine—esophageal cancer	0.000175	0.00179	CcSEcCtD
Salicylate-sodium—Convulsion—Methotrexate—esophageal cancer	0.000175	0.00179	CcSEcCtD
Salicylate-sodium—Salicylic acid—PTGS2—esophageal cancer	0.000175	0.0233	CrCbGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—SOD2—esophageal cancer	0.000172	0.00399	CbGpPWpGaD
Salicylate-sodium—Chest pain—Methotrexate—esophageal cancer	0.000172	0.00176	CcSEcCtD
Salicylate-sodium—Confusional state—Methotrexate—esophageal cancer	0.000166	0.0017	CcSEcCtD
Salicylate-sodium—Anaphylactic shock—Methotrexate—esophageal cancer	0.000165	0.00168	CcSEcCtD
Salicylate-sodium—Infection—Methotrexate—esophageal cancer	0.000164	0.00167	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Capecitabine—esophageal cancer	0.000163	0.00167	CcSEcCtD
Salicylate-sodium—Hyperhidrosis—Methotrexate—esophageal cancer	0.000159	0.00163	CcSEcCtD
Salicylate-sodium—Asthenia—Capecitabine—esophageal cancer	0.000159	0.00162	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—CYP1B1—esophageal cancer	0.000158	0.00367	CbGpPWpGaD
Salicylate-sodium—Anorexia—Methotrexate—esophageal cancer	0.000157	0.0016	CcSEcCtD
Salicylate-sodium—Pruritus—Capecitabine—esophageal cancer	0.000156	0.0016	CcSEcCtD
Salicylate-sodium—Hypotension—Methotrexate—esophageal cancer	0.000154	0.00157	CcSEcCtD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000152	0.00354	CbGpPWpGaD
Salicylate-sodium—Diarrhoea—Capecitabine—esophageal cancer	0.000151	0.00155	CcSEcCtD
Salicylate-sodium—PTGS1—Biological oxidations—CYP19A1—esophageal cancer	0.000149	0.00345	CbGpPWpGaD
Salicylate-sodium—Salicylic acid—ABCB1—esophageal cancer	0.000149	0.0198	CrCbGaD
Salicylate-sodium—Paraesthesia—Methotrexate—esophageal cancer	0.000148	0.00151	CcSEcCtD
Salicylate-sodium—Dyspnoea—Methotrexate—esophageal cancer	0.000147	0.0015	CcSEcCtD
Salicylate-sodium—Somnolence—Methotrexate—esophageal cancer	0.000146	0.0015	CcSEcCtD
Salicylate-sodium—Dizziness—Capecitabine—esophageal cancer	0.000146	0.00149	CcSEcCtD
Salicylate-sodium—Dyspepsia—Methotrexate—esophageal cancer	0.000145	0.00148	CcSEcCtD
Salicylate-sodium—Decreased appetite—Methotrexate—esophageal cancer	0.000143	0.00146	CcSEcCtD
Salicylate-sodium—Fatigue—Methotrexate—esophageal cancer	0.000142	0.00145	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000142	0.00329	CbGpPWpGaD
Salicylate-sodium—Pain—Methotrexate—esophageal cancer	0.000141	0.00144	CcSEcCtD
Salicylate-sodium—Vomiting—Capecitabine—esophageal cancer	0.000141	0.00144	CcSEcCtD
Salicylate-sodium—Rash—Capecitabine—esophageal cancer	0.000139	0.00143	CcSEcCtD
Salicylate-sodium—Dermatitis—Capecitabine—esophageal cancer	0.000139	0.00142	CcSEcCtD
Salicylate-sodium—Headache—Capecitabine—esophageal cancer	0.000139	0.00142	CcSEcCtD
Salicylate-sodium—Feeling abnormal—Methotrexate—esophageal cancer	0.000136	0.00139	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000135	0.00313	CbGpPWpGaD
Salicylate-sodium—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000135	0.00138	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000133	0.00309	CbGpPWpGaD
Salicylate-sodium—Nausea—Capecitabine—esophageal cancer	0.000131	0.00134	CcSEcCtD
Salicylate-sodium—Urticaria—Methotrexate—esophageal cancer	0.000131	0.00134	CcSEcCtD
Salicylate-sodium—Abdominal pain—Methotrexate—esophageal cancer	0.00013	0.00133	CcSEcCtD
Salicylate-sodium—Body temperature increased—Methotrexate—esophageal cancer	0.00013	0.00133	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CREBBP—esophageal cancer	0.000122	0.00284	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—PTGS2—esophageal cancer	0.000122	0.00282	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000122	0.00282	CbGpPWpGaD
Salicylate-sodium—Hypersensitivity—Methotrexate—esophageal cancer	0.000121	0.00124	CcSEcCtD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000121	0.00281	CbGpPWpGaD
Salicylate-sodium—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—esophageal cancer	0.00012	0.00279	CbGpPWpGaD
Salicylate-sodium—Asthenia—Methotrexate—esophageal cancer	0.000118	0.00121	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000118	0.00273	CbGpPWpGaD
Salicylate-sodium—Pruritus—Methotrexate—esophageal cancer	0.000116	0.00119	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000116	0.00269	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000115	0.00267	CbGpPWpGaD
Salicylate-sodium—Diarrhoea—Methotrexate—esophageal cancer	0.000113	0.00115	CcSEcCtD
Salicylate-sodium—PTGS2—Spinal Cord Injury—TLR4—esophageal cancer	0.000109	0.00254	CbGpPWpGaD
Salicylate-sodium—Dizziness—Methotrexate—esophageal cancer	0.000109	0.00111	CcSEcCtD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CDKN2A—esophageal cancer	0.000107	0.00249	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—BCL2—esophageal cancer	0.000106	0.00245	CbGpPWpGaD
Salicylate-sodium—Vomiting—Methotrexate—esophageal cancer	0.000105	0.00107	CcSEcCtD
Salicylate-sodium—PTGS2—Spinal Cord Injury—NOS2—esophageal cancer	0.000104	0.00241	CbGpPWpGaD
Salicylate-sodium—Rash—Methotrexate—esophageal cancer	0.000104	0.00106	CcSEcCtD
Salicylate-sodium—Dermatitis—Methotrexate—esophageal cancer	0.000104	0.00106	CcSEcCtD
Salicylate-sodium—Headache—Methotrexate—esophageal cancer	0.000103	0.00105	CcSEcCtD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000103	0.00239	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	9.81e-05	0.00228	CbGpPWpGaD
Salicylate-sodium—Nausea—Methotrexate—esophageal cancer	9.78e-05	0.001	CcSEcCtD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	9.5e-05	0.0022	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	9.5e-05	0.0022	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—RB1—esophageal cancer	9.3e-05	0.00216	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CCND1—esophageal cancer	9.06e-05	0.0021	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	8.99e-05	0.00209	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	8.98e-05	0.00208	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CDKN1A—esophageal cancer	8.77e-05	0.00203	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—EP300—esophageal cancer	8.34e-05	0.00194	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	8.17e-05	0.0019	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—BLVRB—esophageal cancer	7.98e-05	0.00185	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—SLC52A3—esophageal cancer	7.98e-05	0.00185	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—SLC52A3—esophageal cancer	7.57e-05	0.00176	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—MYC—esophageal cancer	7.27e-05	0.00169	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—KMT2D—esophageal cancer	7.22e-05	0.00168	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	7.13e-05	0.00165	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—CCND1—esophageal cancer	6.9e-05	0.0016	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CA1—esophageal cancer	6.79e-05	0.00158	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—SLC10A2—esophageal cancer	6.79e-05	0.00158	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	6.38e-05	0.00148	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	6.35e-05	0.00147	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—BLVRB—esophageal cancer	6.34e-05	0.00147	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—SLC52A3—esophageal cancer	6.34e-05	0.00147	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CA2—esophageal cancer	6.21e-05	0.00144	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	6.07e-05	0.00141	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PLCE1—esophageal cancer	5.77e-05	0.00134	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—ADH7—esophageal cancer	5.77e-05	0.00134	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	5.7e-05	0.00132	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	5.66e-05	0.00131	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—FKBP1A—esophageal cancer	5.6e-05	0.0013	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—MYC—esophageal cancer	5.54e-05	0.00129	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	5.47e-05	0.00127	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—DOCK2—esophageal cancer	5.47e-05	0.00127	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—WIF1—esophageal cancer	5.47e-05	0.00127	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—EGFR—esophageal cancer	5.42e-05	0.00126	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CA1—esophageal cancer	5.39e-05	0.00125	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—SLC10A2—esophageal cancer	5.39e-05	0.00125	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	5.32e-05	0.00123	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—ADH1B—esophageal cancer	5.06e-05	0.00117	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—CSNK1A1—esophageal cancer	5.05e-05	0.00117	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CA2—esophageal cancer	4.93e-05	0.00114	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—TYMP—esophageal cancer	4.84e-05	0.00112	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	4.82e-05	0.00112	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CYP26A1—esophageal cancer	4.7e-05	0.00109	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	4.7e-05	0.00109	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—ALOX15—esophageal cancer	4.58e-05	0.00106	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—ADH7—esophageal cancer	4.58e-05	0.00106	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PLCE1—esophageal cancer	4.58e-05	0.00106	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—TP53—esophageal cancer	4.55e-05	0.00106	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.54e-05	0.00105	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.53e-05	0.00105	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTO1—esophageal cancer	4.37e-05	0.00101	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—TPI1—esophageal cancer	4.37e-05	0.00101	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	4.32e-05	0.001	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—ELMO1—esophageal cancer	4.24e-05	0.000984	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—ALDOB—esophageal cancer	4.19e-05	0.000973	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—TPI1—esophageal cancer	4.15e-05	0.000962	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—GSTO1—esophageal cancer	4.15e-05	0.000962	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GAPDH—esophageal cancer	4.04e-05	0.000937	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—ADH1B—esophageal cancer	4.02e-05	0.000932	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CRABP1—esophageal cancer	4e-05	0.000928	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—ALDOB—esophageal cancer	3.97e-05	0.000922	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—TYMP—esophageal cancer	3.84e-05	0.000891	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—HIST1H2BM—esophageal cancer	3.83e-05	0.000888	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—GAPDH—esophageal cancer	3.83e-05	0.000888	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GNG7—esophageal cancer	3.8e-05	0.000883	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.77e-05	0.000874	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CYP26A1—esophageal cancer	3.73e-05	0.000867	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.69e-05	0.000855	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—ALOX15—esophageal cancer	3.64e-05	0.000845	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—ALDH2—esophageal cancer	3.57e-05	0.000827	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTO1—esophageal cancer	3.47e-05	0.000806	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—TPI1—esophageal cancer	3.47e-05	0.000806	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTT1—esophageal cancer	3.39e-05	0.000787	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—XIAP—esophageal cancer	3.38e-05	0.000784	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CYP2A6—esophageal cancer	3.35e-05	0.000778	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.34e-05	0.000775	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—ALDOB—esophageal cancer	3.33e-05	0.000772	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GAPDH—esophageal cancer	3.2e-05	0.000744	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.2e-05	0.000742	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—ENO1—esophageal cancer	3.18e-05	0.000737	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CRABP1—esophageal cancer	3.18e-05	0.000737	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—B2M—esophageal cancer	3.14e-05	0.000729	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PSME1—esophageal cancer	3.13e-05	0.000727	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PSME2—esophageal cancer	3.13e-05	0.000727	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.09e-05	0.000718	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GNG7—esophageal cancer	3.02e-05	0.000701	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—ENO1—esophageal cancer	3.01e-05	0.000699	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PSME2—esophageal cancer	2.97e-05	0.000689	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PSME1—esophageal cancer	2.97e-05	0.000689	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—CALR—esophageal cancer	2.85e-05	0.000661	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—ALDH2—esophageal cancer	2.83e-05	0.000657	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—FBXW7—esophageal cancer	2.76e-05	0.000639	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.73e-05	0.000635	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CYP1B1—esophageal cancer	2.7e-05	0.000627	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTT1—esophageal cancer	2.69e-05	0.000625	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CYP2A6—esophageal cancer	2.66e-05	0.000618	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.65e-05	0.000615	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CYP19A1—esophageal cancer	2.54e-05	0.00059	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PTGS1—esophageal cancer	2.52e-05	0.000585	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—ENO1—esophageal cancer	2.52e-05	0.000585	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PSME1—esophageal cancer	2.49e-05	0.000577	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PSME2—esophageal cancer	2.49e-05	0.000577	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—HMOX1—esophageal cancer	2.32e-05	0.000538	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.27e-05	0.000528	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—TGFBR2—esophageal cancer	2.23e-05	0.000517	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—ABCB1—esophageal cancer	2.23e-05	0.000516	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CYP1B1—esophageal cancer	2.15e-05	0.000498	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—SMAD4—esophageal cancer	2.11e-05	0.000489	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CYP19A1—esophageal cancer	2.02e-05	0.000468	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—HMOX1—esophageal cancer	1.84e-05	0.000427	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.81e-05	0.000419	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—ABCB1—esophageal cancer	1.77e-05	0.00041	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—HIF1A—esophageal cancer	1.73e-05	0.000401	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.68e-05	0.00039	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—NOS2—esophageal cancer	1.57e-05	0.000364	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—NOTCH1—esophageal cancer	1.55e-05	0.000361	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CREBBP—esophageal cancer	1.49e-05	0.000345	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—CREBBP—esophageal cancer	1.41e-05	0.000327	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.34e-05	0.00031	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—NOS3—esophageal cancer	1.33e-05	0.000309	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—NOS3—esophageal cancer	1.26e-05	0.000293	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PTGS2—esophageal cancer	1.22e-05	0.000283	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CREBBP—esophageal cancer	1.18e-05	0.000274	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—ERBB2—esophageal cancer	1.18e-05	0.000274	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—NOS3—esophageal cancer	1.06e-05	0.000245	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—EP300—esophageal cancer	1.01e-05	0.000235	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—CDKN1A—esophageal cancer	1.01e-05	0.000234	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—EP300—esophageal cancer	9.6e-06	0.000223	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—MYC—esophageal cancer	8.37e-06	0.000194	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—EGFR—esophageal cancer	8.18e-06	0.00019	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—EP300—esophageal cancer	8.04e-06	0.000187	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PIK3CA—esophageal cancer	7.49e-06	0.000174	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PIK3CA—esophageal cancer	7.1e-06	0.000165	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PIK3CA—esophageal cancer	5.95e-06	0.000138	CbGpPWpGaD
